

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Target number of patients agreed?	Min. number of patients agreed	Max. number of patients agreed	Target date to recruit patients agreed?	Date agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Date that the trial closed to recruitment	Total number of study participants recruited	Reason for closure of trial	Comments
14/SC/1161	155743	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients.	Number Agreed	30	30	Not Available / Not Agreed			17/04/2018	21	Recruitment Finished	Global competition.
16/EM/0133	184873	A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis	Number Agreed	5	5	Date Agreed	25/07/2017	0	31/05/2018	1	Recruitment Finished	Three additional patients screen failed prior to randomisation. Lack of patients meeting inclusion criteria.
17/EM/0075	222172	Evaluating the tolerance, compliance and acceptability of a nutritionally complete, high energy, high protein, enteral feed in adults ? a pilot study	Range Agreed	5	14	Date Agreed	01/09/2017	7	31/05/2018	9	Recruitment Finished	Target met.

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Target number of patients agreed?	Min. number of patients agreed	Max. number of patients agreed	Target date to recruit patients agreed?	Date agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Date that the trial closed to recruitment	Total number of study participants recruited	Reason for closure of trial	Comments
16/LO/0553	194625	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER LONG-TERM SAFETY AND TOLERABILITY STUDY OF ETC-1002 IN PATIENTS WITH HYPERLIPIDEMIA AT HIGH CARDIOVASCULAR RISK WHO ARE NOT ADEQUATELY CONTROLLED BY THEIR LIPID-MODIFYING THERAPY	Number Agreed	8	8	Not Available / Not Agreed			18/04/2018	8	Recruitment Finished	Target met.
15/SW/0194	185459	A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase 3 study to investigate the efficacy of finerenone on the progression of deterioration of kidney function in patients with type 2 diabetes mellitus and the clinical diagnosis of advanced diabetic kidney disease in addition to standard of care.	Number Agreed	12	12	Date Agreed	14/09/2017	6	08/06/2018	8	Recruitment Finished	High number of patients failed screening tests post consent.

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Target number of patients agreed?	Min. number of patients agreed	Max. number of patients agreed	Target date to recruit patients agreed?	Date agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Date that the trial closed to recruitment	Total number of study participants recruited	Reason for closure of trial	Comments
16/EM/0193	190690	A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The Dal-GenE trial	Number Agreed	6	6	Date Agreed	30/11/2018	2	15/12/2018	2	Recruitment Finished	High number of screen failures.
15/SC/0448	183584	A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase 3 study to investigate the efficacy of finerenone on the reduction of cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and the clinical diagnosis of early diabetic kidney disease in addition to standard of care	Number Agreed	9	9	Date Agreed	24/03/2017	6	08/09/2018	10	Recruitment Finished	Target met.